Biocon Biologics announces USFDA approval for Jobevne biosimilar Bevacizumab

Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis

Fluor to provide EPCM services for pharmaceutical facility in Indiana

This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202

Shin-Etsu Chemical to invest in pharmaceutical cellulose business

L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets

NCLT approves amalgamation of Cohance Lifesciences into and with Suven Pharmaceuticals

The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

J&J to break ground on new biologics facility in North Carolina

New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases

RedHill Biopharma to submit FDA-approved Talicia for UK marketing authorisation

Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes

OneSource Specialty Pharma strengthens its board by appointing new directors

These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance

Bionova opens Fremont process development and pilot plant